Insider Transactions in Q1 2024 at Ultragenyx Pharmaceutical Inc. (RARE)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 11
2024
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
11,509
-4.35%
|
$563,941
$49.93 P/Share
|
|
Mar 07
2024
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
12,195
-17.24%
|
$609,750
$50.87 P/Share
|
|
Mar 01
2024
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
1,011
-0.38%
|
$53,583
$53.76 P/Share
|
|
Mar 01
2024
|
Thomas Richard Kassberg CBO & EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
274
-0.1%
|
$14,522
$53.69 P/Share
|
|
Mar 01
2024
|
Thomas Richard Kassberg CBO & EVP |
BUY
Grant, award, or other acquisition
|
Direct |
18,757
+3.33%
|
-
|
|
Mar 01
2024
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,756
-5.28%
|
$199,068
$53.76 P/Share
|
|
Mar 01
2024
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,757
+10.83%
|
-
|
|
Mar 01
2024
|
Howard Horn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,400
+16.28%
|
-
|
|
Mar 01
2024
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
4,173
-4.47%
|
$221,169
$53.76 P/Share
|
|
Mar 01
2024
|
John Richard Pinion |
SELL
Payment of exercise price or tax liability
|
Direct |
60
-0.06%
|
$3,180
$53.69 P/Share
|
|
Mar 01
2024
|
John Richard Pinion |
BUY
Grant, award, or other acquisition
|
Direct |
18,757
+8.57%
|
-
|
|
Mar 01
2024
|
Dennis Karl Huang |
SELL
Payment of exercise price or tax liability
|
Direct |
470
-0.56%
|
$24,910
$53.69 P/Share
|
|
Mar 01
2024
|
Dennis Karl Huang |
BUY
Grant, award, or other acquisition
|
Direct |
18,757
+9.44%
|
-
|
|
Mar 01
2024
|
Eric Crombez EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,238
-2.47%
|
$65,614
$53.76 P/Share
|
|
Mar 01
2024
|
Eric Crombez EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,400
+27.99%
|
-
|
|
Mar 01
2024
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
341
-0.82%
|
$18,073
$53.76 P/Share
|
|
Mar 01
2024
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
121
-0.29%
|
$6,413
$53.69 P/Share
|
|
Mar 01
2024
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,950
+25.0%
|
-
|
|
Mar 01
2024
|
Emil D Kakkis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
41,560
+3.39%
|
-
|
|
Mar 01
2024
|
Emil D Kakkis President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,417
-3.01%
|
$923,101
$53.69 P/Share
|
|
Mar 01
2024
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,768
-6.63%
|
$252,704
$53.76 P/Share
|
|
Mar 01
2024
|
Erik Harris EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,357
+11.43%
|
-
|
|
Feb 07
2024
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Direct |
30,000
-5.27%
|
$1,350,000
$45.0 P/Share
|
|
Jan 02
2024
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+9.71%
|
$63,000
$21.0 P/Share
|